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Recombinant Human Erythropoietin vs Transfusions 
in the Treatment of Anemia of Prematurity 
A Cost-benefit Analyis 
Theresa I. Shireman, MS, RPh; Peter E. Hilsenrath, PhD; Ronald G. Strauss, MD; 
john A. Widness, MD; Alan H. Mutnick, PharmD 
Obiective: To evaluate the costs relative to the benefits 
of using recombinant human erythropoietin (rHuEPO) 
therapy as an alternative to red blood cell (RBC) trans-
fusions in infants with anemia of prematurity. 
of net savings. Sensitivity analysis was performed. 
Results: The base case analysis yielded a net loss of 
$299.48 per infant. A 54% reduction in the direct prod-
uct costs of rHuEPO therapy yielded a break-even point. 
No other variations in the sensitivity analysis resulted in 
a net savings. 
Design: A cost-benefit analysis of rHuEPO therapy was 
performed based on its use in very-low-birth-weight pre-
mature infants. 
SeHing and Patients: Data were drawn from pub-
lished studies or were provided by the University oflowa 
Hospitals and Clinics, Iowa City. 
Main Oukome Measures: Costs and benefits were ana-
lyzed as a comparison of incurred costs to averted costs. 
Incurred and averted costs of rHuEPO therapy and RBC 
transfusions included direct product costs and estimates 
of costs of adverse events. The analysis was viewed in terms 
Conclusion: Using assumptions based on the curremstate 
of clinical research, it appears that routine use of rHuEPO 
with supplemental RBC transfusions would not gener-
ate any cost savings as an alternative to RBC transfu-
sions alone. As further evidence is compiled on the effi-
cacy of rHuEPO therapy in very-low-birth-weight 
premature infants, the true costs may be better estab-
lished. 
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N ESTIMATED 38 000 in-
fants are born prema-
turely each year in the 
United States. 1•2 Up to 
30 000 will require red 
blood cell (RBC) transfusions for treat-
ment of symptomatic anemia of prematu-
rity.2 Until recently, treatment has been lim-
ited to RBC transfusions. 3 •4 However, 
recombinant human erythropoietin 
(rHuEPO) therapy has been investigated as 
an alternative to RBC transfusions in these 
infants_s-u Results of initial trials of rHuEPO 
therapy in neonates with anemia of pre-
maturity have been mixed but promising. 
Resolution of symptoms, increases in bone 
marrow erythroid activity, blood hemoglo-
bin, hematocrit, and reticulocytes, andre-
ductions in RBC transfusion requirements 
have been reported. 5•7•12 These are out-
comes comparable with those achieved us-
ing RBC transfusions. 
The arrival of rHuEPO as a therapeu-
tic alternative raises the question of rela-
tive cost vs benefit of each treatment. 13·14 
As with other recent advances in pharma-
ceutical technology, rHuEPO has a rela-
tively high direct product price.13 If 
rHuEPO therapy proves to be equivalent 
or superior to RBC transfusions clini-
cally, the potential exists for its wide-
spread adoption. It is important to iden-
tify which option is more effective before 
rHuEPO becomes widely used. 
To our knowledge, only one neo-
natal study has addressed the costs of 
rHuEPO therapy vs RBC transfusions. 10 
See Methods on next page 




The use of rHuEPO remains investigational. Therefore, data 
for this cost-benefit analysis were drawn from studies related 
to its use. Other data were provided by the University oflowa 
Hospitals and Clinics (UIHC), Iowa City, a tertiary care cen-
ter participating in an ongoing multicenter clinical trial of 
rHuEPO therapy in premature infants. These data included 
RBC transfusion requirements and hospital charges for a sample 
of 52 very-low-birth-weight (VLBW) premature infants ( <1500 
g) born betweenjuly 1991 andjanuary 1992. 
The methods for this cost-benefit analysis included the 
following steps: development of a relative measure of costs 
and benefits of rHuEPO therapy, determination of the di-
rect product costs and costs of adverse events associated 
with RBC transfusions, determination of the direct prod-
uct costs and costs of adverse events of rHuEPO therapy, 
selection of base case values for the cost-benefit analysis, 
selection of the variables for the sensitivity analysis, and 
presentation of the results. This analysis used a societal per-
spective and includes all medical resource costs. 
Two types of cost-to-charge ratios were provided with 
the UIHC charge data. They were traditional cost-to-
charge ratios and allowed cost-to-charge ratios. 
Traditional cost-to-charge ratios reflected weights as-
signed to each department on the basis of its proportion of 
UIHC's costs. Each department divided its allotted costs 
among the goods or services it provided. The allowed cost-
to-charge ratio reflected the costs associated with the ap-
propriate diagnosis-related grouping. Allowed costs were 
used in the base case whereas traditional costs were tested 
in the sensitivity analysis. 
MEASUREMENT OF COSTS AND BENEFITS 
Costs and benefits were analyzed as a comparison of in-
curred costs to averted costs. 15 lncurred costs included the 
cost of rHuEPO per neonate plus the cost of any RBC trans-
fusions required by the neonate while receiving rHuEPO. 
Averted costs were the costs of RBC transfusions avoided 
by the use of rHuEPO. Incurred and averted costs of rHuEPO 
therapy and RBC transfusions included direct product costs 
and estimates of costs of adverse events. If averted costs 
exceeded incurred costs, the difference between their total 
costs represented a net savings achieved by using rHuEPO. 
If averted costs were less than incurred costs, the differ-
ence was a net cost. 
This analysis was also viewed in terms of cost-benefit 
ratios. The cost-benefit ratio portrayed the relative magni-
tude of costs to benefits. If the ratio exceeded 1, costs out-
weighed benefits by that multiple. Likewise, for ratios less 
than 1, costs fell below benefits by that relative magnitude. 
VARIABLES FOR THE BASE CASE ANALYSIS 
Incurred costs included the costs of rHuEPO for all treated 
infants and the costs of RBC transfusions that were re-
quired in addition to the rHuEPO. The RBC transfusion costs 
were determined by the number of aliquots and donors re-
quired, the cumulative probability of adverse events, the 
costs per adverse event, and the direct product costs. The 
dosing variables for rHuEPO came from a recently pub-
lished clinical trial.'' Subcutaneous doses of rHuEPO were 
administered 3 days per week for 6 weeks. Over the course 
of a 6-week therapy, each neonate would use 18 vials of 
rHuEPO for an allowed cost of $555.30 per infant. 
Direct product costs of RBC transfusions were deter-
mined by the number of donors (units) the aliquots were 
drawn from and the number of aliquots given, based on the 
sample of 52 VLBW neonates from the UIHC. The num-
bers of aliquots and donors incurred depended on the ef-
ficacy of rHuEPO therapy and the transfusion practice of 
the prescribers. The UIHC data indicated that premature 
infants who were not treated with rHuEPO and who were 
transfused with erythrocytes received a median of six ali-
quots from three donors. The baseline assumption of 
rHuEPO efficacy was that 25% of these donors (0. 75 do-
nors) and aliquots (1.5 aliquots) would still be incurred 
when rHuEPO was used. 11 
The probability of acquiring each type of infection was 
calculated using the national estimates and the binomial 
probability function. 16 The probability of acquiring an in-
fection from one of 1.5 aliquots incurred was multiplied 
by the cost per adverse event and summed across the three 
types of infections. These costs were added to the direct 
product costs of rHuEPO therapy and RBC transfusions to 
get total incurred costs. 
Averted costs included all costs associated with averted 
RBC transfusions. The initial case assumed that 75% of the 
donors (2.25 donors) and aliquots ( 4.5 aliquots) were averted 
when rHuEPO was used. Direct product costs and costs of 
adverse events were computed the same way as incurred 
RBC transfusion costs. 
TRANSFUSION COSTS 
Direct Product Costs 
The costs of RBC transfusions were those associated with 
the acquisition, preparation, and administration of the blood 
products and those of adverse events. It was assumed that 
physician, nursing, and allied health care professional costs 
were identical between infants treated with rHuEPO and 
infants treated with RBC transfusions. Similarly, room and 
boarding costs were excluded because the length of stay 
between treatment groups was not shown to be signifi-
cantly different.'' Direct product costs were based on charges 
from the UIHC. Charges related to the RBC transfusions 
were determined from the billings of the infants who had 
~eceived RBC transfusions (1991 dollars). The itemized 
charges recorded in the hospital bill reflected a summing 
of the various direct costs into one figure. Therefore, de-
lineating the actual number of units of each cost was not 
Continued on next page 
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possible with the data provided. As a best estimate, the item-
ized charges for blood products were multiplied by their 
corresponding cost-to-charge ratios to give the cost by de-
partment. 17 IR 
Based on the itemized bills, transfusion costs con-
sisted of costs incurred in the blood donor center (allowed 
cost-to-charge ratio, 0. 75643) and a minimal charge for the 
intravenous tubing (allowed cost-to-charge ratio, 0.59323) 
used to infuse the blood. These charges are listed in Table 1 . 
Charges were categorized as donor related and aliquot re-
lated. Donor-related charges were incurred for a single unit 
of blood from a single donor. Aliquot-related charges rep-
resented a single RBC transfusion that was drawn from a 
single unit. Several aliquots of blood may have been with-
drawn from a single uni.t of blood. 
If multiple aliquots for the same infant were taken from 
the same unit, the costs of irradiation, cytomegalovirus 
(CMV) screening, and blood product aliquot were not du-
plicated. To determine the direct costs for each infant, the 
number of ailquots received was multiplied by the admin-
istration and processing cost and the intravenous tubing 
cost or the total for aliquot-related costs. Irradiation costs, 
CMV-screening costs, and blood product aliquot costs, which 
were the total donor-related costs, were multiplied by the 
number of donors for each infant. The direct cost per in-
fant was a sum of the aliquot- and donor-related costs. For 
instance, if an infant received two RBC transfusions (or ali-
quots) that were taken from a single donor, the direct cost 
would be $49.73+(2)($47.49)=$144.71. 
Costs of Adverse Events 
The use of RBC transfusions carries numerous risks. 
These risks increase as the number of transfusions in -
creases, especially when the RBCs are obtained from dif-
ferent donors.H Potential blood-borne infections are as-
sociated with viral pathogens that include hepatitis C, 
hepatitis B, human immunodeficiency virus (HIV), and 
CMV.H11·19 These may be fatal or may precipitate seri-
ous morbidity in premature infants. 
Estimates of the costs of adverse events were taken 
from the published cost of illness studies, except for 
CMV infection. All estimates were inflated to 1991 dol-
lars using the medical price index20 Although the rate of 
infection is somewhat controversial, the use of blood 
that tests negative for antibodies to CMV in seronegative 
neonates has virtually eliminated RBC transfusion-
acquired CMV infection when such precautions are 
usedz' Therefore, costs were not measured for 
transfusion-acquired CMV infection. 
The value used for the cost of treatment of hepatitis C 
reflected an estimate of direct and indirect costs of adult treat-
However, those authors did not address costs associ-
ated with adverse events. The potential blood-borne 
infections transmitted by RBC transfusions carry con-
siderable costs. These costs may be even higher in in-
ment discounted over a 15-year period at an unspecified rate. n 
The midrange estimate from that study was $5544 in 1991 
dollars. This estimate excluded newer forms of treatment such 
as transplantation and use of interferon but did include work-
loss costs and the cost of premature death. The hepatitis Besti-
mate ($ 22 4 28 in 1991 dollars) was specific for new-
borns and was based on direct medical care costs that were 
only discounted at 5% per annum over 30 yearsn 
Few studies have been published on the costs of 
treating children who are HlV seropositive or who have 
acquired immunodeficiency syndrome (AIDS). A retro-
spective chart review examined the economic costs of 37 
children who were treated as inpatients for AIDS or 
AIDS-related conditions24 The lifetime cost estimate for 
the medical costs ($87 464 in 1991 dollars) was not dis-
counted. This figure excluded advances in treatment, es-
pecially for pharmaceuticals. Because infants who con-
tract HIV infection as neonates usually survive for less 
than 6 years, long-term work-loss costs were not in-
cluded. 15 
The final estimation of the costs of adverse events 
from RBC transfusions was a function of the probability 
of occurrence and the medical costs for treating each ad-
verse event. The rates for each type of transfusion-
acquired infection were 0.03% for hepatitis C, 0.0005% 
for hepatitis B, and 0.00044% for HIV infection.16.18 The 
national estimates for infections implied that these 
pathogens are randomly distributed in the blood supply. 
Locally specific rates for transfusion-acquired infections 
may vary considerably, especially in areas with higher 
rates of donor infections. Cumulative probability esti-
mates for the number of aliquots (RBC transfusions) in-
curred and averted were computed using the binomial 
probability function. 16 
These estimates did not include all the potential costs 
that are associated with RBC transfusions. Other adverse 
events that could be assessed are associated with develop-
ment and treatment of hemolysis, hyperkalemia, and graft-
vs-host disease secondary to RBC transfusions. 19 Indirect 
and intangible costs include time and productivity losses 
for the parents and the donor and pain and suffering. For 
compensated blood donors, the time and productivity loss 
costs were assumed to be accounted for in the charges for 
blood products. Similar costs for voluntary donors were not 
included. One could argue that volunteers are compen-
sated for their losses through nonmonetary values. By not 
incorporating these costs explicitly, the cost estimate for 
RBC transfusions may be underestimated. Transfusions in 
premature infants can precipitate considerable mental strain 
for parents and relatives. Although this anguish cannot be 
quantified readily, it should affect decisions concerning treat-
ment options. 
fants because of the significant number of RBC trans-
fusions they may receive and the lifelong effects of 
these adverse events. Because the effectiveness of ei-
ther therapy appears to be comparable in terms of 
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COSTS OF rHuEPO THERAPY 
PLUS RBC TRANSFUSIONS 
Direct Product Costs 
Erythropoietin therapy costs included drug acquisition costs, 
costs of preparation and administration (including sup-
plies) , and costs of adverse events. For product acquisition 
costs, the entire vial cost was assessed. Doses for neonates 
would not require the entire contents of the smallest vial 
(2000 U) currently commercially available.30 However, a no-
pen vial was assumed to be used once and discarded per 
manufacturer's recommendations. 
The hospital's charge per 2000-U vial was $40.14. The 
allowed cost for rHuEPO doses under 10 000 U was $30.85 
(cost-to-charge ratio, 0. 76848). These costs included prepa-
ration and administration costs. As with transfusions, pro-
fessional and room costs were not included. The direct prod-
uct costs for any RBC transfusions required by infants 
receiving rHuEPO were calculated as per the preceding sec-
tion and were added to the direct cost of rHuEPO therapy. 
Costs of Adverse Events 
The incidence of adverse events to date with the use of 
rHuEPO in neonates with anemia of prematurity has been 
minimal to nonexistent. The most prevalent was neutrope-
nia, which has not been associated with infections.5•8 •10 If an 
infection were to develop secondary to the neutropenia, its 
costs would have to be incorporated into the costs of rHuEPO 
therapy. However, because no reports have been issued, these 
costs were not quantified. One may speculate, however, that 
the probability of infections developing or other adverse events 
arising will increase as the population of infants who re-
ceive rHuEPO increases. For the purposes of this analysis 
and until future data on adverse events are collected, their 
costs were considered insignificant for rHuEPO therapy. 
The costs of rHuEPO use also did not include iron 
supplementation costs. Most clinical trials suggest that iron 
replacement may be necessary in conjunction with 
rHuEP0.5·8·11 The costs of oral iron products are relatively 
low, and many nurseries for premature infants are already 
treating all of their infants with oral iron as a medication 
or as a supplement to infant formula. As with the direct 
product costs for rHuEPO therapy, the cost of adverse events 
associated with RBC transfusions was included in the cost 
estimates for rHuEPO therapy for infants who still require 
RBC transfusions. 
VARIABLES FOR THE SENSITIVITY A ALYSIS 
The first sensitivity analysis involved substituting tradi-
tional costs for allowed costs. All others were one-way sen-
resolution of the symptoms, the following report de-
tails an analysis aimed at determining which is the 
least costlyY-12 The benefits of rHuEPO therapy are 
principally the averted costs of reducing transfusion 
sitivity analyses of single variables from the base case. The 
rationale for varying the variables in the sensitivity analy-
sis are discussed below. 
Traditional Cost-to-Charge Estimates 
Traditional cost-to-charge ratios gave higher cost esti-
mates than the allowed cost-to-charge ratios. The ratios for 
direct product costs ofRBC transfusions increased to 0.88281 
except for intravenous tubing (0. 71154). The direct prod-
uct cost estimate for rHuEPO used a ratio of 0.89546. 
Direct Product Cost of rHuEPO 
The baseline direct product cost for rHuEPO contained an 
estimate based on the hospital charge per dose. Even as neo-
nates gain weight during the course of therapy, it is unlikely 
that they will require the entire contents of a 2000-U vial. 
Manufacturers may decide to prepare the product in more 
dilute concentrations or smaller vials suitable for infants and 
children. It is unclear what effect such repackaging would 
have on the cost of the product, but it could conceivably lower 
the price. To assess the impact of a reduction in price, the 
allowed cost estimate was decreased by 50% and 75%. The 
resulting costs were $15.43 and $7.71 per vial , respectively. 
Dosing 
The optimal dosing variables for rHuEPO in premature in-
fants remain uncertain. Some studies included five doses 
per week, whereas the more recent clinical trials used three 
doses per week. 11 •12 It is also possible that a shorter dura-
tion of therapy may be effective. To account for a poten-
tially effective less frequent dosing or shorter duration of 
therapy, the use of two vials per week (equivalent to three 
doses per week for 4 weeks or l2 vials) was tested. 
Efficacy 
The base case assumption for efficacy of rHuEPO was that 
75% of the RBC transfusions in tenns of donors and aliquots 
would be averted. 11 Ideally, rHuEPO therapy would avert all 
RBC transfusions, although, because of frequent phle-
botomy requirements in VLBW infants, this is unlikely to oc-
cur. Because the decision to transfuse is based on clinical judg-
ment, the rate of RBC transfusions will vary by institution 
and practitioner31 Given these considerations, the bounds 
of efficacy for rHuEPO therapy were set at 50% and 85%. For 
the lower bound (50%), three aliquots and 1.5 donors would 
be incurred and an equal number would be averted. In the 
case of the 85% efficacy, five aliquots and 2.5 donors would 
be averted, and one aliquot and 0.5 donor would be incurred. 
requirements. The objective of this analysis was to 
evaluate the costs relative to the benefits of using 
rHuEPO by incorporating the direct product costs and 
the costs of adverse events of RBC transfusions. 
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Table 1. Red Blood Cell Direct Product Transfusion Costs* 
Traditional Allowed 
Item Charge, $ Cost,$ Cost,$ 
Donor Related 
Irradiation 31.25/U 27.59 23.64 
CMV screening 10.00/U 8.83 7.56 
Blood product aliquot 24.50/U 21.63 18.53 
Total Donor Related 58.05 49.73 
Aliquot Related 
Administration 
and processing 62.00/ALQ 54.73 46.90 
Processing IV tubing 1.00/ALQ 0.71 0.59 
Total Aliquot Related 55.44 47.49 
* Values are expressed as 1991 dollars. U indicates single unit of blood 
from one donor; CMV, cytomegalovirus; ALO, single aliquot or individual 
transfusion; and IV, intravenous. 
Table 2. Base Case Analysis* 


















*Differences in totals are due to rounding. RBC indicates red blood cell; 
rHuEPO, recombinant human erythropoietin. 
t Values expressed as 1991 dollars. 
RESULTS 
BASE CASE ANALYSIS 
The base case analysis in 1991 dollars of allowed costs 
incurred and averted (per infant) in treating premature 
infants with rHuEPO is shown in Table 2 . The cost-
benefit ratio was 1.81. A net loss of $299.48 per infant 
would be incurred. Approximately 88% of the averted costs 
were direct RBC transfusion costs and the other 12% were 
due to adverse events. The direct product costs of rHuEPO 
accounted for 83% of the incurred costs. 
SENSITIVITY ANALYSIS 
A summary of the results of the sensitivity analyses is pre-
sented m Table 3 . 
Traditional Cost-to-Charge Ratios 
With the higher traditional cost-to-charge ratios, the net 
loss increased to $354.77 per infant. The relative pro-
portion of direct RBC transfusion costs averted in-
creased slightly to 90%. Direct rHuEPO costs still ac-
counted for 83% of incurred costs. 
Direct Product Cost of rHuEPO 
The amount of price reduction did have a significant im-
pact on the cost-benefit ratio. If the allowed cost was re-
duced by 50%, the costs of rHuEPO therapy still would 
outweigh the benefits but only by a narrow margin. The 
net loss would be reduced to $21.91 per infant. On the 
other hand, if allowed costs were reduced by 75%, rHuEPO 
use would yield a net savings of $117.05 per infant. The 
break-even point occurred with approximately a 54% re-
duction in product cost to $14.20 per vial. 
Dosing 
A reduction in the number of doses required given the 
base case assumptions for the other variables and the al-
lowed costs would not generate a financial savings. [f 12 
vials were used in the course of therapy, the net loss would 
fall to $114.37 per infant. 
Efficacy 
The final test of the assumptions was based on the effi-
cacy of rHuEPO therapy. If 50% of the donors and ali-
quots could be averted, the net loss would be $555.30 
per infant. Even with an 85% reduction in the number of 
donors and aliquots incurred, indicating a greater effi-
cacy than in the base case, the financial cost of rHuEPO 
therapy would still outweigh the benefits. The net loss 
would be $215.99 per infant. 
COMMENT 
Although this analysis suggests that rHuEPO therapy 
would not be a cost-effective alternative to RBC trans-
fusions in infants with anemia of prematurity, further con-
sideration must be given to the variables tested. Across 
most of the range of variables tested, the costs of rHuEPO 
therapy exceeded the benefits. The only exception was a 
54% reduction in the direct product costs of rHuEPO. 
It is unlikely that such a cost reduction would be 
possible because those costs include direct material costs 
and the cost of preparation. Of course, the assumption 
that each 2000-U vial would be used once and discarded 
may be questioned. It is conceivable that more than one 
dose could be withdrawn from a vial for use in other pre-
mature infants undergoing therapy concurrently or for 
subsequent doses. Eliminating wastage would improve 
the cost-benefit picture as was seen in the analysis of al-
tering the dosing variables. Reducing the usage from 18 
vials per infant to l2 vials per infant changed the net loss 
from $299.48 to $114.37 per infant. The simultaneous 
treatment of two or more premature infants depends on 
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Table 3. Summary of Sensitivity Analyses* 
Cost per Infant, $ 
variable Incurred Averted 
Traditional cost-to-charge ratio 778.41 423.64 
rHuEPO costs 
50% reduction 391.06 369.15 
75% reduction 252.10 369.15 
Dosing (12 vials) 483.52 369.15 
Efficacy 
50% of transfusions averted 865.77 310.47 
85% of transfusions averted 629.82 413.83 















•Values are expressed as 1991 dollars. rHuEPO indicates recombinant human erythropoietin. 
tRepresents a net gain. 
the probability that a given institution will have two or 
more infants in-house concurrently receiving rHuEPO. 
This is more likely in tertiary care facilities. 
With a 50% reduction in direct product costs, the 
net loss per infant was $21.91. It is arguable that the in-
tangible and indirect costs associated with RBC transfu-
sions may outweigh that financial loss. Taking that ar-
gument from an individual's perspective, exposing infants 
to RBC transfusions may be unbearable and worth avoid-
mg at any cost. (This same argument could be applied to 
all scenarios tested.) From the societal perspective, how-
ever, one would have to quantify those costs for all the 
mfants treated. 
lf rHuEPO therapy is more efficacious than the base-
line estimate, the net loss improves to $215.99. Ongoing 
clinical trials will help to determine the relative efficacy 
of rHuEPO therapy and may identify subgroups of neo-
nates who may not need either RBC transfusions or 
rHuEPO therapy. One would have to control for the vari-
ous transfusion practices at individual hospitals. The me-
dian number of donors and aliquots that VLBW prema-
ture neonates are exposed to at the UIHC may be 
representative of tertiary care facilities , but generalizing 
10 community, general, or other hospitals could be prob-
lematic. The transfusion practices continue to change at 
the UIHC with a steady decline in exposure to donors 
and aliquots.3 This decline may flatten out with or with-
out the adoption of rHuEPO therapy. 
The same holds true for the costs of the adverse events 
associated with RBC transfusions. As the blood supply 
becomes safer, the probabilities of transfusion-acquired 
infections fall. Consequently, their costs decline. As a coun-
tervailing effect, though , one must consider the adverse-
event cost estimates used in this analysis. The estimate 
for hepatitis C was based on an adult population and prob-
ably underestimated the lifetime costs for infants. The 
hepatitis C and HIV estimates excluded newer thera-
pies. Only the hepatitis B estimate was specific for new-
borns and based on more current practice. As for the ex-
clusion of the costs of CMV infection, the assumption 
was that the screen was 100% effective and universally 
employed. Violation of any of these assumptions would 
increase the costs of RBC transfusions. 
The results were reported on a per infant basis. There 
are potentially 38 000 premature infants born in a given 
year. 1·2 Of the 52 VLBW neonates sampled from the UIHC, 
67% were transfused with RBCs. Applying this propor-
tion to the population ofVLBW premature infants yields 
approximately 25 500 infants eligible for rHuEPO therapy. 
Using the net loss in terms of allowed costs from the base 
case, society's medical loss would total over $7.4 mil-
lion. Approximately 57 375 donor exposures and 114 750 
aliquots would be avoided. In addition, 172 cases of hepa-
titis C would be averted. Less than one case each of HIV 
and hepatitis B would be eliminated. 
If rHuEPO becomes approved for the treatment of 
anemia of prematurity, the potential exists for neonates 
to be treated unnecessarily. If a mechanism for deter-
mining which particular subpopulations of premature in-
fants would benefit most from rHuEPO therapy can be 
found, these numbers could be significantly reduced and 
the cost-benefit profile could be altered. Once again, fu-
ture results of clinical trials may indicate better guide-
lines for treatment. 
The outcome measure used in this analysis was 
averted costs stemming from avoided transfusions. In 
that sense, this study was a cost-benefit analysis. An 
alternative assessment would be a cost-effectiveness 
analysis that would allow for the measurement of 
other types of clinical effects.32 Ideally, a prospective 
study would incorporate effectiveness measures such 
as changes in hematocrits and more specific aspects of 
RBC transfusion requirements to test this assumption. 
Simply counting the number of RBC transfusions ad-
ministered is a less than precise measure of outcome. 
These results would help to determine if rHuEPO 
therapy and RBC transfusions provide equally effective 
clinical outcomes. 
Recombinant human erythropoietin is still in the 
clinical trial phase for treatment of anemia of prematu-
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rity. Our analyses suggest that the manufacturer may want 
to consider repackaging the product in smaller dose vi-
als and/or lowering the product price by a significant mar-
gin. Although these results are discouraging, they need 
not dictate the abandonment of a potentially useful prod-
uct. Further evidence is needed to establish the efficacy 
of rHuEPO therapy in this patient population. In addi-
tion, identification of response variation in subpopula-
tions may yield neonates who decidedly benefit more from 
rHuEPO therapy than from RBC transfusions or vice versa. 
One cannot exclude indirect costs entirely from these 
analyses. The indirect costs of transfusing neonates weigh 
heavily on the minds of clinicians, parents, families, and 
others. Although this analysis was done from the soci-
etal perspective, the individual perspectives of these de-
cision makers may lead to different conclusions. 
The resources allocated to financing and provid-
ing health care have been rising rapidly. This has been 
driven in part by new technologies such as rHuEPO 
therapy. Many of these technologies are useful and 
cost-effective whereas others are not. 20 Economic 
analyses of resource allocation in health care will be 
increasingly important as biotechnology leads to new 
and expensive products. 
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